drug asking information concerning the abuse potential of its particular product. On December 9, 1975 another letter to these companies requested manufacturing and distribution data. This massive amount of information has been received and is under review.

Thus, the hearings of this subcommittee have come at a fortuitous time. The testimony given by the witnesses who have appeared here and the conclusions the subcommittee draws from that testimony, together with the information we have been reviewing, will be closely considered by DEA in reaching our judgments on the drugs in question. Then, as contemplated by the Controlled Substances Act, those judgments and the supporting data will be forwarded to HEW through the Food and Drug Administration for the definitive medical and scientific evaluation. Mr. Chairman, it should be said at this point that HEW and FDA have always cooperated fully with DEA in those areas in which our responsibilities are joined. We could not ask for better partners.

This subcommittee has requested information on the current patterns of abuse and diversion of